MYNERVA AG

MYNERVA AG is a Swiss MedTech startup and ETH Zurich spin-off, established in June 2025. The company is based in Zurich and focuses on developing innovative neurostimulating medical devices aimed at reducing chronic pain and restoring the sense of touch for patients with diabetic peripheral neuropathy (DPN) and other neurological conditions. The core product, named Leia, is a wearable device designed as smart socks that incorporate force sensors and electrodes. This device utilizes AI-driven electrical stimulation for non-invasive neurostimulation, helping to alleviate neuropathic pain and restore tactile sensation. This technology is particularly beneficial for improving balance and reducing fall risks in patients experiencing sensory loss. MYNERVA AG is currently in the final stages of development and regulatory approval, with clinical validation already in progress. The company has received several awards, including recognition at the Swiss Italian Startup Awards and the Swiss Technology Award. MYNERVA collaborates with academic institutions for product design and is involved with Wyss Zurich, a prominent research institute. The primary users of their technology are patients suffering from DPN, which affects millions globally.

• Employees 11